Search / 43 results found

from
to
  • Updated

INDIANAPOLIS, Jan. 24, 2022 /PRNewswire/ -- Calumet Specialty Products Partners, L.P. (NASDAQ: CLMT) ("Calumet", "Partnership", "we" or "our") announced the closing of the offering for $325 million 2027 senior unsecured notes (the "Offering").  The Partnership intends to use the net proceeds from the Offering, along with cash on hand, to fund the previously announced redemption of all outstanding 7.75% Senior Notes due 2023 (the "2023 Notes") and pay related expenses.

  • Updated

INDIANAPOLIS, Jan. 12, 2022 /PRNewswire/ -- Calumet Specialty Products Partners, L.P. (NASDAQ: CLMT) (the "Partnership" or "Calumet") and its wholly-owned subsidiary Calumet Finance Corp. announced today that, subject to market conditions, they intend to offer (the "Offering") for sale to eligible purchasers in a private placement under Rule 144A and Regulation S of the Securities Act of 1933, as amended (the "Securities Act"), $300 million in aggregate principal amount of senior unsecured notes due 2027. Calumet intends to use the net proceeds from the Offering, together with cash on hand, to fund the redemption of all of its outstanding 7.75% Senior Notes due 2023 (the "2023 Notes") and pay related expenses.

LAGRANGE — After 36 years of pouring over his economic maps and charts trying to help steer different Indiana communities toward better econom…

  • Updated

ELKHART, Ind., Dec. 7, 2021 /PRNewswire/ -- Patrick Industries, Inc. (NASDAQ: PATK) ("Patrick" or the "Company") announced today the pricing of its private offering of $225,000,000 aggregate principal amount of its convertible senior notes due 2028 (the "Notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Company also granted the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the initial closing date of the offering, up to an additional $33,750,000 aggregate principal amount of the Notes. The sale of the Notes to the initial purchasers is expected to settle on or about December 13, 2021, subject to customary closing conditions, and is expected to result in approximately $217 million in net proceeds to the Company, after deducting the initial purchasers' discount and estimated offering expenses payable by the Company (assuming no exercise of the initial purchasers' option to purchase additional Notes) but before deducting the net cost of the convertible note hedge and warrant transactions referred to below.

  • Updated

WARSAW, Ind., Nov. 30, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") today announced the pricing of the previously announced tender offers (collectively, the "Tender Offers" and each a "Tender Offer") to purchase for cash (i) any and all of its 3.700% Senior Notes due 2023 (the "Any and All Notes") and (ii) up to the aggregate purchase price set forth below (excluding accrued and unpaid interest up to, but not including, the applicable Settlement Date (as defined below) and excluding fees and expenses related to the Tender Offers) (the "Aggregate Maximum Purchase Price") of its 3.550% Senior Notes due 2025 (the "Acceptance Priority Level 1 Notes"), 3.550% Senior Notes due 2030 (the "Acceptance Priority Level 2 Notes"), 4.450% Senior Notes due 2045, 3.050% Senior Notes due 2026, 4.250% Senior Notes due 2035 and 5.750% Senior Notes due 2039 (collectively, the "Maximum Tender Offer Notes," and together with the Any and All Notes, the "Securities"). The Tender Offers are being made upon, and are subject to, the terms and conditions set forth in the Offer to Purchase dated November 15, 2021 (the "Offer to Purchase"), as amended by our press release of earlier today. Tenders of Securities may no longer be withdrawn except in certain limited circumstances where additional withdrawal rights are required by law.